Royalty Pharma (RPRX) Operating Expenses (2019 - 2026)

Royalty Pharma has disclosed Operating Expenses across 8 years of filings, most recently posting $67.5 million for Q1 2026.

• Operating Expenses for Q1 2026 came in at $67.5 million, up 98.26% year-over-year; the trailing twelve-month figure through Mar 2026 was $852.1 million (up 134.46% YoY), and the FY2025 annual result was $818.7 million, down 15.7% from the prior year.
• Operating Expenses came in at $67.5 million for Q1 2026 at Royalty Pharma, down from $233.6 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $1.0 billion in Q4 2022 to a low of -$170.4 million in Q3 2024.
• The 5-year median for Operating Expenses is $233.6 million (2025), against an average of $273.5 million.
• Peak annual rise in Operating Expenses reached 1479.41% in 2024, while the deepest fall reached 144.27% in 2024.
• Royalty Pharma's Operating Expenses stood at $1.0 billion in 2022, then tumbled by 101.61% to -$16.8 million in 2023, then jumped by 1479.41% to $232.1 million in 2024, then climbed by 0.64% to $233.6 million in 2025, then slumped by 71.09% to $67.5 million in 2026.
• The last three Operating Expenses figures came in at $67.5 million (Q1 2026), $233.6 million (Q4 2025), and $182.1 million (Q3 2025), per Business Quant data.